News
![Ipsen Provides Update on Palovarotene Clinical Programs](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Ipsen Provides Update on Palovarotene Clinical Programs
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) announced today it will begin to reinitiate palovarotene dosing in patients 14 years of age and older currently participating in its
![Quidel’s Lyra® SARS-CoV-2 Assay Receives Authorization for Expanded Use for Molecular Detection of COVID-19; Also Receives CE Mark, Health Canada Authorization](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Quidel’s Lyra® SARS-CoV-2 Assay Receives Authorization for Expanded Use for Molecular Detection of COVID-19; Also Receives CE Mark, Health Canada Authorization
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel’s Lyra®
![U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for EUCRISA® (crisaborole) ointment, 2%, extending
![Gilead: Corona-Zulassung kein Kaufgrund – andere Aktie im Fokus!](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Gilead: Corona-Zulassung kein Kaufgrund – andere Aktie im Fokus!
Einige Anleger meinen derzeit, mit einer Aktie wie der von Gilead Sciences (WKN: 885823) die große Chance zu ergreifen, von der Corona-Krise zu profitieren. Hohe Kursgewinne lauern aber bei den
![Gilead: Chance auf Corona-Zulassung steigt!](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Gilead: Chance auf Corona-Zulassung steigt!
Der Corona-Krise zum Trotz klettert die Aktie des US-Pharmakonzerns Gilead Sciences (WKN: 885823) nahe Jahreshoch. Allein in den letzten zwei Handelstagen ging es für das Papier rund +15% nach oben.
![Agilent Technologies Announces Cash Dividend of 18 Cents Per Share](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Agilent Technologies Announces Cash Dividend of 18 Cents Per Share
Agilent Technologies Inc. (NYSE: A) today announced that a quarterly dividend of 18 cents per share of common stock will be paid on April 22, 2020, to all shareholders of record as of the close of
![Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns
Pfizer Inc. (NYSE: PFE) announced today that given the unique circumstances of the COVID-19 pandemic and Pfizer’s responsibility to prioritize the health and safety of colleagues and invited
![Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch
Pfizer Inc. (NYSE:PFE) announced today that JADE COMPARE (B7451029) met its co-primary efficacy endpoints. The Phase 3 study evaluated the safety and efficacy of abrocitinib, an investigational
![Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older
Pfizer Inc. (NYSE:PFE) today announced top-line results from one of its Phase 3 studies (NCT03760146), which evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine
![Quidel Receives Emergency Use Authorization for Molecular COVID-19 Diagnostic Assay](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Quidel Receives Emergency Use Authorization for Molecular COVID-19 Diagnostic Assay
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
![Agilent Technologies to Adjourn Annual Meeting Until April 17, 2020](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Agilent Technologies to Adjourn Annual Meeting Until April 17, 2020
Agilent Technologies, Inc. (NYSE: A) today announced plans to adjourn its annual meeting of stockholders, originally scheduled to be held March 18, 2020, due to public health considerations
![Humana Foundation Donates $500,000 in Support of Coronavirus Pandemic Relief and Recovery Efforts](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Humana Foundation Donates $500,000 in Support of Coronavirus Pandemic Relief and Recovery Efforts
The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM), announced today it will provide $500,000 in support of coronavirus (COVID-19) relief and recovery efforts, partnering with three
![Pfizer Invites Public to View and Listen to Webcast of April 28 Conference Call with Analysts](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pfizer Invites Public to View and Listen to Webcast of April 28 Conference Call with Analysts
Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, April 28, 2020. The purpose
![Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine
Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the companies have agreed to a letter of intent regarding the co-development and distribution
![Agilent Introduces CrossLab Connect Services for Lab-wide Asset Monitoring](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Agilent Introduces CrossLab Connect Services for Lab-wide Asset Monitoring
Agilent Technologies Inc. (NYSE: A) announced today an extension to its digital lab capabilities with Agilent CrossLab Asset Monitoring, an advanced service for laboratories seeking increased
![Pfizer Outlines Five-Point Plan to Battle COVID-19](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Pfizer Outlines Five-Point Plan to Battle COVID-19
Pfizer today issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19.
Dr. Albert Bourla, Chairman
![Agilent Receives Two Scientists’ Choice Awards](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Agilent Receives Two Scientists’ Choice Awards
Agilent Technologies Inc. (NYSE: A) today announced that two of the company’s instruments have received Scientists’ Choice awards. The Agilent 8890 GC system won for Best New Separations Product
![Humana Takes Steps to Care for Members in Response to Coronavirus](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Humana Takes Steps to Care for Members in Response to Coronavirus
Humana Inc. (NYSE: HUM) announced today several actions in response to the increased spread of the coronavirus (COVID-19).
“As we navigate the spread of the coronavirus, our top priority is the
![Susan Hockfield Elected to Pfizer’s Board of Directors](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Susan Hockfield Elected to Pfizer’s Board of Directors
Pfizer Inc. (NYSE: PFE) today announced the election of Dr. Susan Hockfield to its Board of Directors, effective immediately. Dr. Hockfield, age 68, was also appointed to the Regulatory and
![Veeva Announces Fiscal 2020 Fourth Quarter and Fiscal Year 2020 Results](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Veeva Announces Fiscal 2020 Fourth Quarter and Fiscal Year 2020 Results
Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fiscal fourth quarter ended January 31, 2020
![Agilent Introduces Three New Microarrays for Prenatal and Postnatal Research](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Agilent Introduces Three New Microarrays for Prenatal and Postnatal Research
Agilent Technologies Inc. (NYSE: A) today introduced three new microarrays to meet the needs of cytogenetic laboratories conducting both prenatal and postnatal research.
The new Agilent
![Agilent and Visiopharm Co-promote Advanced Digital Precision Pathology Solutions](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Agilent and Visiopharm Co-promote Advanced Digital Precision Pathology Solutions
Agilent Technologies Inc. (NYSE: A) and Visiopharm today announced that they have entered a co-marketing agreement. The announcement is happening at the USCAP 109th Annual Meeting being held
![Waters Drives Materials Sciences Innovation Forward at Pittcon 2020 with New Instrument Introductions](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Waters Drives Materials Sciences Innovation Forward at Pittcon 2020 with New Instrument Introductions
Waters Corporation (NYSE:WAT) today introduced new products that bring greater productivity and efficiency to materials science research. The new Discovery™ X3 Differential Scanning Calorimeter
![Agilent Technologies Announces Webcasts for Investment Community](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Agilent Technologies Announces Webcasts for Investment Community
Agilent Technologies Inc. (NYSE: A) today announced the following webcasts for the investment community.
40th Annual Cowen And Company Healthcare Conference
Tuesday, March 3, 2020 at 10:00 a.m
![James Quincey Elected to Pfizer’s Board of Directors](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
James Quincey Elected to Pfizer’s Board of Directors
Pfizer Inc. (NYSE: PFE) today announced the election of James Quincey to its Board of Directors, effective immediately. Mr. Quincey, age 55, was also appointed to the Compensation Committee and the